The different faces of cutaneous lupus erythematosus

Giornale Italiano di Dermatologia e Venereologia

Volumn 144, Issue 2, 2009, Pages 135-147

  Renner, R ^a,b,c   Sticherling, M ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c NONE   (Germany)

Author keywords

Autoimmunity; Lupus erythematosus, cutaneous, diagnosis; Lupus erythematosus, cutaneous, drug therapy

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; BETAMETHASONE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLOROQUINE; CIMETIDINE; CORTICOSTEROID; DAPSONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROXYCHLOROQUINE; ISONIAZID; MEPACRINE; METHOTREXATE; MINOCYCLINE; MOMETASONFUROAT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PIMECROLIMUS; PREDNICARBATE; PREDNISOLONE; RETINOID; SPIRONOLACTONE; TACROLIMUS; TERBINAFINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE SKIN LUPUS ERYTHEMATOSUS; ALLERGIC PNEUMONITIS; ALOPECIA; ATRIOVENTRICULAR BLOCK; BLOOD CELL COUNT; BONE MARROW DEPRESSION; BULLOUS LUPUS ERYTHEMATOSUS; DIABETES MELLITUS; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG TOLERABILITY; DRY SKIN; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEMOLYSIS; HEMOLYTIC ANEMIA; HISTOPATHOLOGY; HUMAN; HYPERKERATOSIS; HYPERTENSION; INFECTION; KIDNEY DISEASE; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS PROFUNDUS; LUPUS ERYTHEMATOSUS TUMIDUS; METHEMOGLOBINEMIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEWBORN LUPUS ERYTHEMATOSUS; OSTEOPOROSIS; PATHOGENESIS; PLACENTAL TRANSFER; RETINOPATHY; REVIEW; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS; STOMATITIS; SUN EXPOSURE; ULCER; VOMITING;

EID: 67649503173     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Tebbe B, Orfanos CE. Prognosis of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T (eds). Cutaneous lupus erythemtatosus. Berlin, Heidelberg, New York, Tokyo: Springer; 2004. p. 187-204.
2. Gilliam JN. The cutaneous signs of lupus erythematosus. Cont Educ Fam Phys 1977;6:37-40.
3. Costner MI, Sontheimer RD, Provost TT. Lupus erythematosus. In: Sontheimer RD, Provost TT: Cutaneous manifestation for rheumatic diseases. Philadelphia: Williams & Wilkins; 2003 .p. 15-64.
4. Provost TT. Nonspecific cutaneous manifestations of systemic lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T (eds.) Cutaneous lupus erythematosus. Heidelberg: Springer; 2004 .p. 93-106.
5. Kuhn A, Ruzicka T. Classification of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T (eds) Cutaneous Lupus Erythematosus. Heidelberg: Springer; 2004 .p. 53-58
6. Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005;125:889-894
7. Bonilla-Martinez ZL, Albrecht J, Troxel AB, Taylor L, Okawa J, Dulay S et al. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol 2008;144:173-180 (Pubitemid 351287000)
8. Kuhn A, Sticherling M, Bonsmann G. Clinical manifestations of cutaneous lupus erythematosus. J Deutsch Dermatol Ges 2007;5:1124-1140
9. Mond CB, Peterson MG, Rothfield NF. Correlation of anti-Ro antibody with photosensitivity rash in systemic lupus erythematosus patients. Arthritis Rheum 1989;32:202-204 (Pubitemid 19056408)
10. Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 2006;24:348-362. (Pubitemid 44332871)
11. Grant JM. Annular vesicular lupus erythematosus. Cutis 1981;28:90-92 (Pubitemid 11071726)
12. Wechsler HL, Stavrides A. Systemic lupus erythematosus with anti-Ro antibodies: clinical, histologic und immunologic findings. J Am Acad Dermatol 1982;6:73-83. (Pubitemid 12197910)
13. Herrero C, Bielsa I, Front J, Lozano F, Ercilla G, Lecha M et al. Subacute cutaneous lupus erythematosus: clinicopathologic findings in thirteen cases. J Am Acad Dermatol 1988;19:1057-1062 (Pubitemid 19001533)
14. Zeitouni NC, Funaro D, Cloutier RA, Gagné E, Claveau J. Redefining Rowell's syndrome. Br J Dermatol 2000;142:343-346 (Pubitemid 30117709)
15. Chaudhry SI, Murphy LA, White IR. Subacute cutaneous lupus erythematosus: a paraneoplastic dermatosis? Clin Exp Dermatol 2005;30:655-658
16. Renner R, Sticherling M. Incidental cases of subacute cutaneous lupus erythematosus in association with malignancy. Eur J Dermatol 2008;18:700-704
17. Brenner S, Golan H, Gat A, Bialy-Golan A. Paraneoplastic subacute cutaneous lupus erythematosus: report of a case associated with cancer of the lung. Dermatology 1997;194:172-174 (Pubitemid 27129094)
18. Massone C, Kodama K, Salmhofer W, Abe R, Shimizu H, Parodi A et al. Lupus erythemtaosus panniculitis (lupus profundus): clinical, histopathological and molecular analysis of nine cases. J Cutan Pathol 2005;32:396-404.
19. Requena L, Sanchez Yue E. Panniculitis (Part II). Mostly lobular panniculitis. J Am Acad Dermatol 2001;45:325. (Pubitemid 32800489)
20. Lee-Kirsch MA, Gong M, Schulz H, Ruschendorf F, Stein A, Pfeiffer C et al. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet 2006;79:731-737
21. Lee-Kirsch MA, Chowdhury D, Harvey S, Gong M, Senenko L, Engel K et al. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med 2007;85:531-537 (Pubitemid 46701663)
22. Ruiz H, Sanchez JL. Tumid lupus erythematosus. Am J Dermatopathol 1999;21:356-360 (Pubitemid 29359939)
23. Kuhn A, Sonntag M, Richter-Hintz D, Oslislo C, Megahed M, Ruzicka T et al. Phototesting in lupus erythematosus tumdus - review of 60 patients. Photochem Photobiol 2001;73:532-536 (Pubitemid 33720367)
24. Paradela S, Martínez-Gómez W, Fernández-Jorge B, Castiñeiras I, Yebra-Pimentel T, Llinares P et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus. Lupus 2007;16:741-745 (Pubitemid 47517871)
25. Ting W, Stone MS, Racila D, Scofield RH, Sontheimer RD. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesion. Lupus 2004;13:941-950 (Pubitemid 39664954)
26. Boh EE. Neonatal lupus erythematosus. Clin Dermatol 2004;22:125-188 (Pubitemid 38834262)
27. Kuhn A, Herrmann M, Kleber S, Beckmann-Welle M, Fehsel K, Martin-Villalba A et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum 2006;54:939-950
28. Kuhn A, Bijl M. Pathogenesis of cutaneous lupus erythematosus. Lupus 2008;17:389-393 (Pubitemid 351798714)
29. Vasoo S. Drug-induced lupus: an update. Lupus 2006;15:757-761
30. Weger W, Kränke B, Gerger A, Salmhofer W, Aberer E. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine. J Am Acad Dermatol 2008;59(2 Suppl 1):S4-6. (Pubitemid 351952412)
31. Hivnor CM, Hudkins ML, Bonner B. Terbinafine-induced subacute cutaneous lupus erythematosus. Cutis 2008;81:156-157
32. Adachi A, Horikawa T. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. J Dermatol 2007;34:473-476 (Pubitemid 46956593)
33. Vabre-Latre CM, Bayle P, Marguery MC, Gadroy A, Durand D, Bazex J. Worsening of subacute lupus erythematosus induced by infliximab. Ann Dermatol Venerol 2005;132:349-353 (Pubitemid 40675715)
34. Suess A, Sticherling M. Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin. Int J Dermatol 2008;47:83-86
35. Shimaoka Y, Hatamochi A, Hamasaki Y, Suzuki H, Ikeda H, Yamazaki S. Discoid lupus erythematosus exacerbated by contact dermatitis caused by use of squaric acid dibutylester for topical immunotherapy in a patient with alopecia areata. J Dermatol 2008;35:151-153
36. Schneider SW, Staender S, Schlüter B, Luger TA, Bonsmann G. Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. Arch Dermatol 2006;142:115-116 (Pubitemid 43107378)
37. Richez C, Dumoulin C, Schaeverbeke T. Infliximab induced chilblain lupus in a patients with rheumatoid arthritis. J Rheumatol 2005;32:760-761 (Pubitemid 40524717)
38. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW et al. National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Ann Intern Med 2003;139:137-147 (Pubitemid 38129105)
39. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes. (KDIGO). Kidney Int 2005;67:2089-2100
40. Sticherling M, Bonsmann G, Kuhn A. Diagnostic approach and treatment of cutaneous lupus erythematosus. J Deutsch Dermatol Ges 2008;6:48-61.
41. Cardinali C, Caproni M, Fabbri P. The composition of the lupus band test (LBT) on the sun-protected non-lesional (SPNL) skin in patients with cutaneous lupus erythematosus (CLE). Lupus 1999;8:755-760
42. Boehncke WH, Ochsendorf F, Paeslack I, Kaufmann R, Zollner TM. Decorative cosmetics improve the qualitiy of life in patients with disfiguring skin diseases. Eur J Dermatol 2002;12:577-580 (Pubitemid 35440799)
43. Wollina U, Hansel G. The use of topical calcineurin inhibitors in lupus erythematosus: an overview. J Eur Acad Dermatol Venereol 2008;22:1-6.
44. Ueki H. Koebner phenomenon in lupus erythematosus with spezial consideration of clinical findings. Autoimmun Rev 2005;4:219-223 (Pubitemid 40704706)
45. Ermann J, Bermas BL. The biology behind the new therapies for SLE. Int J Clin Pract 2007;61:2113-2119 (Pubitemid 350077396)
46. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002;109:1377-1382 (Pubitemid 34700934)
47. Ochsendorf FR. Antimalarial. In: Kuhn A, Lehmann P, Ruzicka T (eds). Cutaneous lupus erythematosus. Heidelberg: Springer; 2004 .p. 347-372
48. Casado E, Gratacos J, Tolosa C, Martinez JM, Ojanguren I, Ariza A et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients with cutaneous lupus erythematosus (CLE). Ann Rheum Dis 2006;65:385-390
49. Von Schmiedeberg S, Rönnau AC, Schuppe HC, Specker C, Ruzicka T, Lehmann P. Kombination der Antimalariamittel Mepacrin und Chloroquin bei therapieresistentem Lupus erythematodes. Hautarzt 2000;51:82-85
50. Costedoat-Chalumeau N, Amoura Z, Hulot JS, Lechat P, Piette JC. Hydroxychloroquine in systemic lupus erythematosus. Lancet 2007;269:1257-1258
51. Rahman P, Gladman DD, Urowitz MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998; 25:1716-9. (Pubitemid 28439264)
52. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000;42:983-987 (Pubitemid 30368665)
53. Bohm I, Bruns A, Schupp G, Bauer R. ANCA-positive lupus erythematodes profundus. Successful therapy with low dosage dapsone. Hautarzt 1998;49:403-407
54. Kosseifi SG, Guha B, Nassour DN, Chi DS, Krishnaswamy G. The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. J Occup Med Toxicol 2006;1:9. (Pubitemid 46724440)
55. Reinhold U, Buttgereit F. High dosage steroid pulse therapy. Is there an indication in dermatology? Hautarzt 2000;51:738-745
56. Pisoni CN, Obermoser G, Cuadrado MJ, Sanchez FJ, Karim Y, Sepp NT et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 2005;23:393-396 (Pubitemid 40823550)
57. Schanz S, Ulmer A, Rassner G, Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002;147:174-178 (Pubitemid 34779458)
58. Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001;45:142-144 (Pubitemid 32655712)
59. Boehm I, Bieber T. Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 2001;137:235-236 (Pubitemid 32163685)
60. Tu Y, Peng X, Wang L, Wang H, Sun Z, Zheng H et al. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. MMF in Induction Therapy for Active Lupus Nephritis in Mainland China Study Group. Lupus 2008;17:622-629
61. Houssiau FA, Ginzler EM. Current treatment of lupus nephritis. Lupus 2008;17:426-430 (Pubitemid 351798721)
62. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997;23:739-755 (Pubitemid 27490240)
63. Boehm I, Wenzel J. FACS monitoring of lymphocyte-subsets in patients with discoid and subacute-cutaneous lupus erythematosus receiving low-dose methotrexate. Scan J Rheumatol 2002;31:216-220 (Pubitemid 34971878)
64. Kuhn A, Specker C, Ruzicka T, Lehmann P. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2002;46:600-603
65. Mimouni D, Nousari HC. Inhibitors of purine and pyrimidne synthesis: mycophenolate, azathioprine, leflunomide. Dermatol Ther 2002;15:311-316 (Pubitemid 36133858)
66. Layseca-Espinosa E, Pedraza-Alva G, Montiel JL, del Río R, Fierro NA, González-Amaro R et al. T cell aggregation induced through CD43: intracellular signals and inhibition by the immunomodulatory drug leflunomide. J Leukoc Biol 2003;74:1083-1093 (Pubitemid 38040330)
67. Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 2001;10:480-483 (Pubitemid 32675047)
68. Tam LS, Li EK, Wong CK, Lam CW, Szeto CC. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 2004;13:601-604 (Pubitemid 39145490)
69. Schneider SW, Staender S, Schlüter B, Luger TA, Bonsmann G. Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. Arch Dermatol 2006;142:115-116 (Pubitemid 43107378)